Chlamydia – Pipeline Insight, 2020

Chlamydia – Pipeline Insight, 2020

  • November 2020 •
  • 60 pages •
  • Report ID: 5982682 •
  • Format: PDF
“Chlamydia – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chlamydia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Chlamydia Understanding

Chlamydia: Overview
Chlamydia is a sexually transmitted infection (STI) caused by a bacteria called chlamydia trachomatis. Usually it doesn’t cause any symptoms and can be easily treated with antibiotics. However, if it isn’t treated early it can spread to other parts of your body and lead to long-term health problems.
Signs of chlamydia in women include:
• increase in vaginal discharge
• pain or burning when urinating (peeing)
• pain during sex and/or bleeding after sex
• pain in the lower stomach – especially when having sex
• bleeding between periods and/or heavier periods.
Signs of chlamydia in men include:
• white, cloudy or watery discharge from the penis
• pain or burning when urinating
• pain and/or swelling in the testicles.
Getting tested for chlamydia is easy and doesn’t hurt. A healthcare professional will ask for a urine (pee) sample and/or take a swab from the area that might be infected. This is usually the lower part of the womb (cervix) or the vagina for women, and the tip of the penis (urethra) for men.
Chlamydia can usually be effectively treated with antibiotics. More than 95% of people will be cured if they take their antibiotics correctly.
• Azithromycin – given as 2 or 4 tablets at once.
• Doxycycline – given as 2 capsules a day for a week.

Chlamydia Emerging Drugs Chapters
This segment of the Chlamydia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chlamydia Emerging Drugs
• EVO100: Evofem Biosciences
The investigational drug candidate EVO100 vaginal gel is designed to reduce certain vaginal infections by:
• Balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria
• Using a different mechanism of action that may help to address drug resistance concerns
Further product details are provided in the report……..

Chlamydia: Therapeutic Assessment
This segment of the report provides insights about the different Chlamydia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Chlamydia
There are approx. 10+ key companies which are developing the therapies for Chlamydia. The companies which have their Chlamydia drug candidates in the most advanced stage, i.e. phase II include, Evofem Biosciences.
• Phases
report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Chlamydia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chlamydia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chlamydia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chlamydia drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Chlamydia R&D. The therapies under development are focused on novel approaches to treat/improve Chlamydia.
Chlamydia Report Insights
• Chlamydia Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chlamydia Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chlamydia drugs?
• How many Chlamydia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chlamydia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chlamydia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chlamydia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Evofem Inc.
• Warner Chilcott
• Shire
• Okogen
• NovaBay Pharmaceuticals
• Melinta Therapeutics
• Laboratoires Thea
• IVIEW Therapeutics Inc.
• Forest Laboratories
• Endo Pharmaceuticals
• ActivBiotics Pharma, LLC

Key Products
• EVO100
• FST-100
• OKG-0301
• NVC-422
• solithromycin
• Azithromycin
• IVIEW-1201
• Ceftaroline fosamil for Injection|IV Ceftriaxone|Placebo|Clarithromycin
• PRO 2000
• Rifalazil